AstraZeneca fight rumbles on
The proposed takeover of AstraZeneca is proving to be one of the most controversial yet.
The £63bn takeover offer for Anglo-Swedish pharmaceutical group AstraZeneca by its US rival Pfizer is shaping up to be one of the most controversial takeover battles to involve a UK-based company.
British politicians fear that the enlarged Pfizer would cut research spending in the UK, endangering jobs and damaging Britain's science base. On the other side of the Atlantic, there has been considerable criticism of Pfizer's proposal to domicile the combined group in the UK for tax purposes.
In the past week, Pfizer's chief executive appeared before MPs in an attempt to reassure them about his firm's plans for investment and employment. Meanwhile, the firm is reported to be planning an increased hostile bid if it's unable to win the support of AstraZeneca's board.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
What the commentators said
Normally in these situations, the takeover will go ahead as seen in Kraft's acquisition of Cadbury in 2010. Dangle the prospect of "jam today" in front of shareholders and they will bite, regardless of whether it represents a good long-term outcome.
This reflects the "dysfunctional nature of the relationship" between company management, fund managers, the investors in the funds they run and the rest of society, agreed John Plender in the FT.
Executives are incentivised to boost short-term earnings through takeovers and cost-cutting, while fund managers are judged on short-term performance and leap at the chance to make a profit.
Yet there is ample evidence that takeovers are "a highly effective mechanism for uncreative destruction" rather than a boon to either investors or the economy: take Pfizer itself, which has spent $240bn on three big takeovers in 15 years, yet has a market cap today of just $185bn. "The only consistent winners are the investment bankers and other advisers."
That may be true in general, but this particular deal "is a poor test case for almost any question about big corporate acquisitions", said Edward Hadas on Breakingviews.com.
"The would-be US acquirer, the British target, the UK government and the whole pharmaceutical industry are all tainted. They are guilty, respectively, of a tax fixation, cutting research, empty words and inadequate drug discovery. So there is really no one with the moral authority to say whether this is a good deal."
The best outcome would be for the UK and US to tackle the weakest part of the bid: Pfizer's attempt to game the tax system. If the firm is still interested after that, it can come back with a fresh bid.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
Cris Sholto Heaton is an investment analyst and writer who has been contributing to MoneyWeek since 2006 and was managing editor of the magazine between 2016 and 2018. He is especially interested in international investing, believing many investors still focus too much on their home markets and that it pays to take advantage of all the opportunities the world offers. He often writes about Asian equities, international income and global asset allocation.
Cris began his career in financial services consultancy at PwC and Lane Clark & Peacock, before an abrupt change of direction into oil, gas and energy at Petroleum Economist and Platts and subsequently into investment research and writing. In addition to his articles for MoneyWeek, he also works with a number of asset managers, consultancies and financial information providers.
He holds the Chartered Financial Analyst designation and the Investment Management Certificate, as well as degrees in finance and mathematics. He has also studied acting, film-making and photography, and strongly suspects that an awareness of what makes a compelling story is just as important for understanding markets as any amount of qualifications.
-
Investors pull money from UK equities as government warns of “painful” Budget
The government’s post-election honeymoon period has been short-lived, and investors are shying away from UK equities as a result
By Katie Williams Published
-
Top global fintech companies to invest in
One British fintech hogs the headlines, but there are two top performers in the US. We explain where you should put your money
By David C. Stevenson Published
-
AstraZeneca’s Covid troubles could see it pull out of making vaccines
News AstraZeneca has suffered a series of setbacks with its Covid-19 jab and may exit the inoculation subsector altogether. Matthew Partridge reports
By Dr Matthew Partridge Published
-
AstraZeneca’s shareholders rebel over pay
News Shareholders in AstraZeneca have rebelled over proposals to raise bonus levels for its bosses.
By Dr Matthew Partridge Last updated
-
If you'd invested in: AstraZeneca and Mitie Group
Features Pharmaceutical giant AstraZeneca is expected to grow its earnings, while outsourcer Mitie's share rice has been hit by a series of profit warnings.
By Alice Gråhns Published
-
Major setback for AstraZeneca
Features Pharma giant AstraZeneca was banking on a key clinical trial for its cancer drugs. It was a flop. What comes next? asks Alice Gråhns.
By Alice Gråhns Published
-
A revolutionary new cancer treatment – and the blue-chip stock set to benefit
Features A new kind of cancer therapy could make a big difference to survival rates - and transform the fortunes of one big UK drugs company. Matthew Partridge explains.
By Dr Matthew Partridge Published
-
Company in the news: AstraZeneca
Features Drugs giant AstraZeneca is at the centre of a takeover tussle with US rival Pfizer. Phil Oakley looks at how the shares have been affected.
By Phil Oakley Published
-
Buy Big Pharma – the deal spree could be just beginning
Features With pharmaceutical stocks still looking cheap and some very smart deals being done, it’s a good time to buy in to the sector. John Stepek explains how.
By John Stepek Published